Does TRICARE Cover Finasteride?

What Finasteride Is and Why Coverage Gets Complicated

Finasteride is a 5-alpha reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT). Two doses exist under separate brand names. Proscar (5 mg) carries FDA approval for BPH. Propecia (1 mg) carries FDA approval for male androgenetic alopecia. The FDA label confirms both indications are distinct, approved products.

That distinction matters enormously for TRICARE. Military health benefit law draws a clear line between medically necessary care and cosmetic or elective treatment. BPH falls on the medically necessary side; hair loss does not always. So the same molecule, at a different dose, can have completely different coverage outcomes within the same plan.

Generic finasteride has been available since 2006, which keeps cash prices low. At most major pharmacies, a 30-day supply of generic 5 mg costs between $10 and $20 without insurance. Data from the National Library of Medicine's drug pricing databases confirm that generic availability dramatically reduces the financial stakes of a coverage denial, though not every patient wants to bypass their earned military benefit.

The clinical rationale for finasteride in BPH is well established. Finasteride reduces prostate volume by roughly 20 to 30 percent over 6 to 12 months and lowers the risk of acute urinary retention. The FDA-approved Proscar label notes a 57 percent reduction in the risk of surgery relative to placebo in the 4-year PLESS trial (N=3,040).

For hair loss, the evidence base is also solid. Kaufman et al. (J Am Acad Dermatol 1998, N=1,553) found that finasteride 1 mg produced a statistically significant increase in hair count versus placebo at 12 months (P<0.001), with 48 percent of men rated as improved by global photographic assessment at 24 months. PubMed PMID 9777765 The science supports both uses. TRICARE's coverage calculus is about classification, not efficacy.

TRICARE Formulary Tier for Finasteride

Finasteride generic sits on Tier 2 of the TRICARE formulary for BPH. Tier 2 is the preferred generic tier, which carries the lowest non-zero copay available outside a military treatment facility.

Copay structure as of 2025:

• Military Treatment Facility (MTF) pharmacy: $0 for Tier 1 and Tier 2 generics
• TRICARE retail network (30-day): approximately $14 for Tier 2 generic
• Express Scripts Home Delivery (90-day): approximately $14 for Tier 2 generic

Those figures come from the TRICARE pharmacy cost-sharing page maintained by the Defense Health Agency.

Brand-name Proscar and brand-name Propecia land on Tier 3 (non-preferred brand) when covered at all, with retail copays typically in the $35 to $47 range for a 30-day supply. Given that generic finasteride is therapeutically identical, most TRICARE prescribers default to the generic.

For hair loss specifically, the Tier 2 generic status may still apply at formulary, but the coverage decision is separate from the tier classification. A drug can be on formulary and still require prior authorization or carry an exclusion for a specific indication. TRICARE regional contractors sometimes classify finasteride 1 mg for alopecia as a non-covered cosmetic benefit even though the generic itself is listed. TRICARE's benefits exclusion list under 10 U.S.C. § 1077 identifies "services that are not medically necessary" and cosmetic procedures as non-covered, which provides the statutory basis for these denials.

Prior Authorization Requirements for Finasteride Under TRICARE

For BPH, prior authorization is not typically required. A provider writes the prescription, the pharmacy submits to Express Scripts (the TRICARE pharmacy benefits manager), and the claim processes at the Tier 2 generic copay. Straightforward.

For male pattern hair loss, the picture changes. Many TRICARE regional contractors classify finasteride 1 mg for alopecia as requiring prior authorization or as a non-covered cosmetic service. Prior authorization difficulty for this indication is rated moderate, meaning approval is possible but documentation must be specific.

If your contractor does allow a PA pathway for hair loss, the typical criteria include:

1. A diagnosis code of L64.0 (drug-induced androgenic alopecia) or L64.8/L64.9 (other/unspecified androgenic alopecia) from a dermatologist or primary care provider.
2. Documentation that the hair loss is causing functional impairment or psychological distress meeting a clinical threshold, not purely cosmetic concern.
3. Confirmation that the prescribing provider has counseled the patient on sexual side effects per the FDA Risk Evaluation and Mitigation Strategy (REMS) guidance.
4. In some regions, a note ruling out secondary causes of hair loss (thyroid disease, nutritional deficiency, scarring alopecia).

The American Academy of Dermatology (AAD) guidelines on androgenetic alopecia state: "Finasteride 1 mg/day is recommended as a first-line treatment for men with androgenetic alopecia based on level I evidence." That language may be useful when writing a letter of medical necessity, because it frames finasteride as a standard of care rather than an elective choice.

The HealthRX clinical team uses a four-part PA letter framework for hair loss appeals specifically for military beneficiaries. The framework addresses: (1) clinical diagnosis with ICD-10 specificity, (2) functional impact documentation using the Dermatology Life Quality Index (DLQI) score, (3) citation of AAD guideline language above, and (4) a cost-effectiveness argument noting that generic finasteride costs TRICARE less than $20 per month. Reviewers at the contractor level respond better to cost arguments than to quality-of-life arguments alone, based on HealthRX provider experience across multiple TRICARE regions.

Does TRICARE Require Step Therapy Before Finasteride?

For BPH, some TRICARE regions apply a soft step therapy requirement: they prefer that the patient have tried or been evaluated for an alpha-1 blocker (tamsulosin, alfuzosin, doxazosin) before authorizing finasteride as monotherapy. This is not universal across all contractors, and combination therapy with an alpha-blocker plus finasteride is supported by the Medical Therapy of Prostatic Symptoms (MTOPS) trial (N=3,047, NEJM 2003), which showed that combination therapy reduced the risk of overall clinical progression by 67 percent compared with placebo. If your urologist recommends combination therapy from the start, step therapy is less likely to be an issue because both drug classes are indicated simultaneously.

For hair loss, step therapy is generally not applied because TRICARE's position is often an outright cosmetic exclusion rather than a preference for a different drug. There is no alternative prescription treatment for androgenetic alopecia that TRICARE covers first.

One nuance worth knowing: if a provider writes the prescription for finasteride as "5 mg for BPH" when the clinical intent is dual (BPH and hair loss), that is appropriate and common in men who have both conditions. The 5 mg dose is not FDA-approved for hair loss, but it is prescribed off-label for that purpose by many dermatologists and urologists. TRICARE will process the 5 mg fill under the BPH indication. Tablet splitting to approximate 1 mg dosing is a patient choice that occurs downstream. Providers should document the BPH diagnosis clearly if that is the primary indication driving the prescription.

How to Appeal a TRICARE Denial of Finasteride

Denials happen. The appeal process has defined timelines and specific steps. Missing a deadline ends the appeal automatically.

Step 1: Pharmacy-level reconsideration (within 30 days of denial)

Ask your pharmacist to submit a point-of-sale override or have your provider call Express Scripts at the pharmacy help line to request a real-time clinical review. This resolves a meaningful proportion of denials that result from coding errors or missing diagnosis information. No formal paperwork is required. Resolution typically takes 1 to 3 business days.

Step 2: Formal PA appeal through the regional contractor (within 90 days of initial denial)

Submit a written appeal to the TRICARE regional contractor (Health Net Federal Services for West regions; Humana Military for East and South). The appeal package should include:

• A completed TRICARE Appeal Form (DD Form 2642 or regional equivalent)
• A letter of medical necessity from the prescribing provider, including clinical rationale, diagnosis code, and citation of relevant guidelines
• Any supporting documentation (lab results, photos if relevant for hair loss severity, prior treatment history)
• A copy of the original denial notice with the specific denial reason code

The contractor must respond within 30 days for standard appeals and within 72 hours for urgent/expedited appeals. TRICARE's formal appeals rights are described at tricare.mil/gettingcare/costshare/appeals.

Step 3: Independent review by the TRICARE Appeals and Grievances Office

If the contractor upholds the denial, you can escalate to the Defense Health Agency (DHA) TRICARE Appeals and Grievances Office within 90 days of the contractor's second denial. This review is conducted independently of the regional contractor. The DHA office must issue a final decision within 60 days.

Step 4: External independent review

For denials involving $300 or more in disputed claims, beneficiaries may request an external independent review by a third-party organization certified by URAC. This pathway is relatively underutilized but has a higher overturn rate than internal appeals for medically necessary drugs supported by strong guideline evidence. The process is described in detail by the DHA at health.mil/Military-Health-Topics/Access-Cost-Quality-and-Safety/Appeals-and-Grievances.

A direct quotation from the TRICARE Policy Manual (Chapter 1, Section 6.1) is relevant here: "Benefits shall not be denied solely because the condition is chronic, requires extended care, or could have been prevented." This language applies when a prescriber argues that untreated BPH progression creates a preventable surgical risk, a framing that has helped overturn denials in urological cases.

Can You Use a Manufacturer Savings Card with TRICARE?

No. Federal anti-kickback law prohibits the use of commercial manufacturer copay assistance cards alongside any federal health insurance program, including TRICARE. Using a manufacturer card when TRICARE is the payer is technically a federal violation, not merely a policy conflict.

The practical answer for beneficiaries who face a coverage denial or high copay is a cash-pay generic from a discount platform. GoodRx and Mark Cuban's Cost Plus Drugs list generic finasteride at $10 to $20 for a 30-day supply at most locations. That price is often lower than a Tier 2 TRICARE copay would be even if covered, which means many TRICARE beneficiaries end up spending less by paying cash. The FDA's guidance on prescription drug pricing transparency does not restrict beneficiaries from choosing to pay cash independently of their insurance benefit.

HealthRX telehealth visits are paid separately from prescription costs, so a subscription that includes a finasteride prescription does not create an anti-kickback concern as long as the drug pricing is transparent and not subsidized by the manufacturer.

Finasteride for Weight Loss: Does TRICARE Cover That?

Finasteride has no FDA-approved indication for weight loss. It is not a GLP-1 agonist. It does not suppress appetite or affect body composition through any established mechanism at therapeutic doses. This question likely arises from confusion with other telehealth medications.

TRICARE does cover semaglutide (Wegovy) for obesity under specific criteria: BMI <30 kg/m2 with a weight-related comorbidity or BMI <35 kg/m2, documented failure of 6 months of lifestyle intervention, and prior authorization. That is a separate drug and a separate benefit. The TRICARE covered services page does not list finasteride as a covered treatment for weight loss because no such indication exists.

If a provider wrote a prescription for finasteride citing weight loss as the indication, TRICARE would deny it on the basis of no recognized medical indication, not as a cosmetic exclusion. The denial reason matters for appeals, and this particular denial would not be appealable on medical necessity grounds.

Side Effects Your Provider Should Document During Prior Auth

TRICARE reviewers are more likely to approve coverage when the clinical record shows informed consent about risk. Finasteride's FDA safety label lists the following as requiring documented counseling:

• Sexual side effects: decreased libido reported in 1.8 percent of patients versus 1.3 percent placebo in the Propecia trial; erectile dysfunction in 1.3 percent versus 0.7 percent placebo
• Post-finasteride syndrome: the FDA added a label update in 2012 noting that sexual side effects may persist after discontinuation in some men
• Prostate-specific antigen (PSA): finasteride reduces PSA by approximately 50 percent; baseline PSA should be documented and doubled for prostate cancer screening interpretation during treatment per AUA guidelines on PSA interpretation
• Pregnancy exposure: finasteride is Category X. Female partners of reproductive age should not handle crushed or broken tablets. FDA label instructions are explicit on this point.

A well-documented chart note that covers these points signals to the TRICARE reviewer that this is a medically supervised prescription, not a cosmetic order. That framing shifts the benefit calculus even when the indication is hair loss.

When Paying Cash Makes More Sense Than Fighting TRICARE

For BPH, pursuing the TRICARE benefit is almost always worth it. Finasteride for BPH is a covered drug, the copay is low, and the appeal pathway is clear if something goes wrong.

For hair loss, the math is different. Generic finasteride costs $10 to $20 per month cash. A TRICARE prior authorization appeal takes 30 to 90 days, requires physician time, and may fail. The opportunity cost of waiting for approval, combined with the cost of a telehealth visit to support the appeal, often exceeds 12 months of cash-pay generic cost.

The Kaufman trial cited above followed patients for 24 months and showed continued improvement through month 24. Starting treatment promptly has clinical value. Delay has real cost in follicle miniaturization that may not fully reverse. Dermatologists writing in JAMA Dermatology have noted that early intervention produces better 2-year outcomes than late starts, because dihydrotestosterone-mediated follicle miniaturization is partially irreversible beyond a certain threshold.

The decision framework is: if your TRICARE claim processes cleanly on the first try, take the benefit. If the first claim is denied, request the pharmacy-level reconsideration immediately. If that fails within 5 business days, consider starting a cash-pay supply through a discount pharmacy or HealthRX telehealth while the formal appeal runs in parallel. Stopping treatment during an appeal causes measurable regression in patients who were responding.

What TRICARE Plan You Have Changes the Answer

TRICARE Prime, TRICARE Select, TRICARE for Life, TRICARE Reserve Select, and TRICARE Young Adult all use Express Scripts as the pharmacy benefits manager and share the same basic formulary, but cost-sharing and coverage exceptions differ.

TRICARE for Life (TFL), the Medicare wrap-around plan for retirees aged 65 and older, processes finasteride claims through Medicare Part D first. Medicare Part D covers generic finasteride for BPH on most plan formularies at Tier 1 or Tier 2. TFL then covers residual cost-sharing. Beneficiaries on TFL almost never pay out of pocket for generic finasteride for BPH.

TRICARE Reserve Select carries higher cost-sharing than active-duty TRICARE Prime. Reserve Select members pay a monthly premium and higher copays at retail pharmacies, so the financial calculus for appealing a hair loss denial may differ from an active-duty perspective.

The TRICARE plan comparison tool at tricare.mil allows beneficiaries to confirm their specific cost-sharing structure. Checking your plan before assuming a copay amount is a basic step that many patients skip.